echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > JamA sub-journal nearly 30,000 people data tips: prevention of bone pine fractures bisphosphonates continue to use for how long

    JamA sub-journal nearly 30,000 people data tips: prevention of bone pine fractures bisphosphonates continue to use for how long

    • Last Update: 2021-01-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    In September 2015, the American Society for The Study of Bone and Minerals (ASBMR) task force recommended that low-risk patients consider deactivation for a period of time after five years of continuous treatment with bisphosphonates, while women at high risk of fractures continue to receive ongoing treatment.
    , the Working Group noted that the recommendation was based on limited evidence.
    fda's analysis of long-term data from major clinical trials also found that the benefits of continuous treatment of bisphosphonates for more than 3-5 years remain unclear.
    to explore the issue further, a team led by Kaiser Permanente researchers at Kaiser Permanente, a leading U.S. medical institution, conducted a large-scale queue study that provided new insights into the timing of ongoing drug use in nearly 30,000 people.
    findings were published recently in JAMA Network Open, a sub-issue of the Journal of the American Medical Association.
    : The JAMA Network Open study included data on a total of 29,685 women aged 45-80 in Kaiser Permanente's Southern California and Northern California health systems.
    all women have been treated with oral bisphosphonates, including sodium alenphosphate, sodium lithionate, or sodium icingate, and completed the first five years of treatment between 2002 and 2014.
    women who had previously received intravenous bisphosphonates or ethythnosphates were not included.
    According to follow-up treatment, the women were divided into three groups: bisphosphonate therapy was terminated at the beginning of the study, continued to take the drug for 2 years (stop the drug for 6 months), or continued treatment for 5 years (stop the drug for 6 months).
    after the first five years of treatment, about 37 percent of women were diagnosed with osteoporosis.
    507 hip fractures occurred during follow-up five years after the end of the first five years of treatment.
    5-year cumulative hip fractures in each group were as follows: 5 years after initial treatment: 23.0 cases/1000 persons, 2 years of continued medication: 20.8 cases/1000 persons, 5 years of continued medication: 26.8/1000 People Statistics from different treatment groups show that women who took oral bisphosphonates for more than 7 or 10 years did not have an additional reduction in the overall risk of hip fractures over the next five years (year 6-10) compared to women who had only been treated for five years.
    , the rate of hip fractures was similar to that of women who continued treatment, regardless of the six-month interval between initial treatment and non-continued treatment.
    but interestingly, women treated for seven years were observed to have lower hip fracture rates in 3-4 years (8-9 years) after 5 years of initial medication than women who had been treated for 10 years.
    on the survival rate of no hip fractures in the next 5 years (6-10 years).
    treatment plan 1: 5 years after the initial treatment stopped the drug (orange); treatment plan 2: additional drug use 2 years (blue); treatment plan 3: additional drug use 5 years (grey); A - there is a 6-month interval; B- no interval period; solid line is adjusted statistical results, dotted line is a rough statistic.
    (Photo Source: Reference 1) The team points out that this means that attention should be paid to the potential benefits of two years of continued medication, rather than five years, for the prevention of hip fractures, and whether the potential benefits vary for women at different risk of fractures.
    References to the World, Izano MA, et al., (2020). Bisphosphonate Treatment Beyond 5 Years and Hip Fracture Risk in Older Women. JAMA Netw Open, DOI: 10.1001/jamanetworkopen.2020.25190 [2] Long-Term Oral Bisphosphonates Get Little Love in Study. Retrieved December 8, 2020, from the Chinese Society of Gerontology and Geriatrics Osteoporosis Branch of the Committee of Experts in Obstetrics and Gynecology and training with perinatal osteoporosis prevention and control. Expert Consensus on Osteoporosis Prevention and Control in Peri-Menopaedic and Post-Menopapaanic Women (2020)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.